Savara (SVRA)

• Market cap: $816M
• 1 day: -3.49%
• 5 days: -5.03%
• 1 month: 16.25%
• 3 months: 60.23%
• 6 months: 29.69%
• Year to date: 35.18%
• 1 year: 14.01%
• 5 years: 284.26%
• 10 years: -87.12%
• Sector: Healthcare
• Industry: Biotechnology

About: Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.

Employees: 59